Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 264

1.

Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.

Mariano R, Messina S, Kumar K, Kuker W, Leite MI, Palace J.

JAMA Netw Open. 2019 Oct 2;2(10):e1912732. doi: 10.1001/jamanetworkopen.2019.12732.

PMID:
31596489
2.

Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral.

Moccia M, Prados F, Filippi M, Rocca MA, Valsasina P, Brownlee WJ, Zecca C, Gallo A, Rovira A, Gass A, Palace J, Lukas C, Vrenken H, Ourselin S, Gandini Wheeler-Kingshott CAM, Ciccarelli O, Barkhof F; MAGNIMS Study Group.

Ann Neurol. 2019 Aug 6. doi: 10.1002/ana.25571. [Epub ahead of print]

PMID:
31385358
3.

Lifespan normative data on rates of brain volume changes.

Battaglini M, Gentile G, Luchetti L, Giorgio A, Vrenken H, Barkhof F, Cover KS, Bakshi R, Chu R, Sormani MP, Enzinger C, Ropele S, Ciccarelli O, Wheeler-Kingshott C, Yiannakas M, Filippi M, Rocca MA, Preziosa P, Gallo A, Bisecco A, Palace J, Kong Y, Horakova D, Vaneckova M, Gasperini C, Ruggieri S, De Stefano N; MAGNIMS Study Group.

Neurobiol Aging. 2019 Sep;81:30-37. doi: 10.1016/j.neurobiolaging.2019.05.010. Epub 2019 May 22.

PMID:
31207467
4.

The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations.

Rodríguez Cruz PM, Cossins J, Estephan EP, Munell F, Selby K, Hirano M, Maroofin R, Mehrjardi MYV, Chow G, Carr A, Manzur A, Robb S, Munot P, Wei Liu W, Banka S, Fraser H, De Goede C, Zanoteli E, Conti Reed U, Sage A, Gratacos M, Macaya A, Dusl M, Senderek J, Töpf A, Hofer M, Knight R, Ramdas S, Jayawant S, Lochmüller H, Palace J, Beeson D.

Brain. 2019 Jun 1;142(6):1547-1560. doi: 10.1093/brain/awz107.

5.

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM.

N Engl J Med. 2019 Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.

PMID:
31050279
6.

Myasthenia gravis.

Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM.

Nat Rev Dis Primers. 2019 May 2;5(1):30. doi: 10.1038/s41572-019-0079-y. Review.

PMID:
31048702
7.

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.

Palace J, Lin DY, Zeng D, Majed M, Elsone L, Hamid S, Messina S, Misu T, Sagen J, Whittam D, Takai Y, Leite MI, Weinshenker B, Cabre P, Jacob A, Nakashima I, Fujihara K, Pittock SJ.

Brain. 2019 May 1;142(5):1310-1323. doi: 10.1093/brain/awz054.

8.

Visibility and representation of women in multiple sclerosis research.

Thomson A, Horne R, Chung C, Marta M, Giovannoni G, Palace J, Dobson R.

Neurology. 2019 Apr 9;92(15):713-719. doi: 10.1212/WNL.0000000000007276. Epub 2019 Mar 20. Review.

9.

A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis.

Coe S, Cossington J, Collett J, Soundy A, Izadi H, Ovington M, Durkin L, Kirsten M, Clegg M, Cavey A, Wade DT, Palace J, DeLuca GC, Chapman K, Harrison JM, Buckingham E, Dawes H.

J Neurol Neurosurg Psychiatry. 2019 May;90(5):507-513. doi: 10.1136/jnnp-2018-319496. Epub 2019 Mar 4.

PMID:
30833449
10.

Multiple sclerosis and the risk of systemic venous thrombosis: A systematic review.

Ahmed O, Geraldes R, DeLuca GC, Palace J.

Mult Scler Relat Disord. 2019 Jan;27:424-430. doi: 10.1016/j.msard.2018.10.008. Epub 2018 Oct 17. No abstract available.

PMID:
30642566
11.

Brain and cord imaging features in neuromyelitis optica spectrum disorders.

Cacciaguerra L, Meani A, Mesaros S, Radaelli M, Palace J, Dujmovic-Basuroski I, Pagani E, Martinelli V, Matthews L, Drulovic J, Leite MI, Comi G, Filippi M, Rocca MA.

Ann Neurol. 2019 Mar;85(3):371-384. doi: 10.1002/ana.25411. Epub 2019 Jan 28.

PMID:
30635936
12.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

13.

Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.

Mealy MA, Mossburg SE, Kim SH, Messina S, Borisow N, Lopez-Gonzalez R, Ospina JP, Scheel M, Yeshokumar AK, Awad A, Leite MI, Arango JJ, Paul F, Palace J, Kim HJ, Levy M.

Mult Scler Relat Disord. 2019 Feb;28:64-68. doi: 10.1016/j.msard.2018.12.011. Epub 2018 Dec 9.

PMID:
30554040
14.

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.

Juryńczyk M, Jacob A, Fujihara K, Palace J.

Pract Neurol. 2019 Jun;19(3):187-195. doi: 10.1136/practneurol-2017-001787. Epub 2018 Dec 8. Review.

PMID:
30530724
15.

Racial differences in neuromyelitis optica spectrum disorder.

Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, Kim HJ.

Neurology. 2018 Nov 27;91(22):e2089-e2099. doi: 10.1212/WNL.0000000000006574. Epub 2018 Oct 26.

PMID:
30366977
16.

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

Nervenarzt. 2018 Dec;89(12):1388-1399. doi: 10.1007/s00115-018-0607-0. Review. German.

PMID:
30264269
17.

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD.

Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Yoshiki T, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ.

Neurology. 2018 Oct 23;91(17):e1642-e1651. doi: 10.1212/WNL.0000000000006392. Epub 2018 Sep 26.

18.

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.

Palace J, Duddy M, Lawton M, Bregenzer T, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Lilford R, Dobson C.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):251-260. doi: 10.1136/jnnp-2018-318360. Epub 2018 Sep 21.

19.

Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study.

Oertel FC, Havla J, Roca-Fernández A, Lizak N, Zimmermann H, Motamedi S, Borisow N, White OB, Bellmann-Strobl J, Albrecht P, Ruprecht K, Jarius S, Palace J, Leite MI, Kuempfel T, Paul F, Brandt AU.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1259-1265. doi: 10.1136/jnnp-2018-318382. Epub 2018 Jun 19.

PMID:
29921610
20.

The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes.

Rodríguez Cruz PM, Palace J, Beeson D.

Int J Mol Sci. 2018 Jun 5;19(6). pii: E1677. doi: 10.3390/ijms19061677. Review.

21.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. Review.

22.

Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging.

Storelli L, Rocca MA, Pagani E, Van Hecke W, Horsfield MA, De Stefano N, Rovira A, Sastre-Garriga J, Palace J, Sima D, Smeets D, Filippi M; MAGNIMS Study Group.

Radiology. 2018 Aug;288(2):554-564. doi: 10.1148/radiol.2018172468. Epub 2018 May 1.

PMID:
29714673
23.

Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder.

Hacohen Y, Palace J.

Neurology. 2018 May 22;90(21):947-948. doi: 10.1212/WNL.0000000000005619. Epub 2018 Apr 25. No abstract available.

PMID:
29695599
24.

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

Cerqueira JJ, Compston DAS, Geraldes R, Rosa MM, Schmierer K, Thompson A, Tinelli M, Palace J.

J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850. doi: 10.1136/jnnp-2017-317509. Epub 2018 Apr 4. No abstract available.

25.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Palace J; MAGNIMS study group.

Nat Rev Neurol. 2018 Apr;14(4):199-213. doi: 10.1038/nrneurol.2018.14. Epub 2018 Mar 9. Review. Erratum in: Nat Rev Neurol. 2018 Mar 20;14 (4):213.

PMID:
29521337
26.

A practical approach to the diagnosis of spinal cord lesions.

Mariano R, Flanagan EP, Weinshenker BG, Palace J.

Pract Neurol. 2018 Jun;18(3):187-200. doi: 10.1136/practneurol-2017-001845. Epub 2018 Mar 2. Review.

PMID:
29500319
27.

Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.

De Stefano N, Giorgio A, Tintoré M, Pia Amato M, Kappos L, Palace J, Yousry T, Rocca MA, Ciccarelli O, Enzinger C, Frederiksen J, Filippi M, Vrenken H, Rovira À; MAGNIMS study group.

Mult Scler. 2018 Feb;24(2):214-221. doi: 10.1177/1352458517717808. No abstract available.

PMID:
29451440
28.

Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.

Wilson R, Makuch M, Kienzler AK, Varley J, Taylor J, Woodhall M, Palace J, Leite MI, Waters P, Irani SR.

Brain. 2018 Apr 1;141(4):1063-1074. doi: 10.1093/brain/awy010.

29.

A protocol for a randomised double-blind placebo-controlled feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue in people with relapsing and remitting multiple sclerosis (RRMS).

Coe S, Collett J, Izadi H, Wade DT, Clegg M, Harrison JM, Buckingham E, Cavey A, DeLuca GC, Palace J, Dawes H.

Pilot Feasibility Stud. 2018 Jan 23;4:35. doi: 10.1186/s40814-018-0230-7. eCollection 2018.

30.

Therapeutic strategies for congenital myasthenic syndromes.

Lee M, Beeson D, Palace J.

Ann N Y Acad Sci. 2018 Jan;1412(1):129-136. doi: 10.1111/nyas.13538. Review.

PMID:
29381222
31.

Serological and experimental studies in different forms of myasthenia gravis.

Vincent A, Huda S, Cao M, Cetin H, Koneczny I, Rodriguez Cruz PM, Jacobson L, Viegas S, Jacob S, Woodhall M, Nagaishi A, Maniaol A, Damato V, Leite MI, Cossins J, Webster R, Palace J, Beeson D.

Ann N Y Acad Sci. 2018 Feb;1413(1):143-153. doi: 10.1111/nyas.13592. Epub 2018 Jan 29. Review. Erratum in: Ann N Y Acad Sci. 2018 Apr;1417(1):130.

PMID:
29377162
32.

Myasthenic syndromes due to defects in COL13A1 and in the N-linked glycosylation pathway.

Beeson D, Cossins J, Rodriguez Cruz PM, Maxwell S, Liu WW, Palace J.

Ann N Y Acad Sci. 2018 Feb;1413(1):163-169. doi: 10.1111/nyas.13576. Epub 2018 Jan 24. Erratum in: Ann N Y Acad Sci. 2018 Apr;1417(1):131.

PMID:
29363764
33.

Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, Kalser J, Poulat AL, Maurey H, Ganelin-Cohen E, Wassmer E, Hemingway C, Forsyth R, Hennes EM, Leite MI, Ciccarelli O, Anlar B, Hintzen R, Marignier R, Palace J, Baumann M, Rostásy K, Neuteboom R, Deiva K, Lim M.

JAMA Neurol. 2018 Apr 1;75(4):478-487. doi: 10.1001/jamaneurol.2017.4601.

34.

Atypical periodic paralysis and myalgia: A novel RYR1 phenotype.

Matthews E, Neuwirth C, Jaffer F, Scalco RS, Fialho D, Parton M, Raja Rayan D, Suetterlin K, Sud R, Spiegel R, Mein R, Houlden H, Schaefer A, Healy E, Palace J, Quinlivan R, Treves S, Holton JL, Jungbluth H, Hanna MG.

Neurology. 2018 Jan 30;90(5):e412-e418. doi: 10.1212/WNL.0000000000004894. Epub 2018 Jan 3.

35.

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.

Jurynczyk M, Probert F, Yeo T, Tackley G, Claridge TDW, Cavey A, Woodhall MR, Arora S, Winkler T, Schiffer E, Vincent A, DeLuca G, Sibson NR, Isabel Leite M, Waters P, Anthony DC, Palace J.

Acta Neuropathol Commun. 2017 Dec 6;5(1):95. doi: 10.1186/s40478-017-0495-8.

36.

Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial.

McKee JB, Cottriall CL, Elston J, Epps S, Evangelou N, Gerry S, Kennard C, Kong Y, Koelewyn A, Kueker W, Leite MI, Palace J, Craner M.

Mult Scler. 2019 Feb;25(2):246-255. doi: 10.1177/1352458517742979. Epub 2017 Nov 27.

PMID:
29172994
37.

Clinical presentation and prognosis in MOG-antibody disease: a UK study.

Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J.

Brain. 2017 Dec 1;140(12):3128-3138. doi: 10.1093/brain/awx276. Erratum in: Brain. 2018 Apr 1;141(4):e31.

PMID:
29136091
38.

A mathematical model of cellular swelling in Neuromyelitis optica.

Laranjeira S, Symmonds M, Palace J, Payne SJ, Orlowski P.

J Theor Biol. 2017 Nov 21;433:39-48. doi: 10.1016/j.jtbi.2017.08.020. Epub 2017 Aug 23.

PMID:
28843390
39.

Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody.

Hacohen Y, Messina S, Gan HW, Wright S, Chandratre S, Leite MI, Fallon P, Vincent A, Ciccarelli O, Wassmer E, Lim M, Palace J, Hemingway C.

Mult Scler. 2018 Apr;24(5):679-684. doi: 10.1177/1352458517726593. Epub 2017 Aug 14.

PMID:
28803524
40.

Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder.

Combes AJE, Matthews L, Lee JS, Li DKB, Carruthers R, Traboulsee AL, Barker GJ, Palace J, Kolind S.

Neuroimage Clin. 2017 Jun 16;16:17-22. doi: 10.1016/j.nicl.2017.06.019. eCollection 2017.

41.

Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.

Yates RL, Esiri MM, Palace J, Jacobs B, Perera R, DeLuca GC.

Ann Neurol. 2017 Aug;82(2):259-270. doi: 10.1002/ana.24997. Epub 2017 Aug 19.

PMID:
28719020
42.

Differential diagnosis of neuromyelitis optica spectrum disorders.

Kim SM, Kim SJ, Lee HJ, Kuroda H, Palace J, Fujihara K.

Ther Adv Neurol Disord. 2017 Jul;10(7):265-289. doi: 10.1177/1756285617709723. Epub 2017 May 24. Review.

43.

A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE).

Absoud M, Brex P, Ciccarelli O, Diribe O, Giovannoni G, Hellier J, Howe R, Holland R, Kelly J, McCrone P, Murphy C, Palace J, Pickles A, Pike M, Robertson N, Jacob A, Lim M.

Health Technol Assess. 2017 May;21(31):1-50. doi: 10.3310/hta21310.

44.

Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.

Sisay S, Lopez-Lozano L, Mickunas M, Quiroga-Fernández A, Palace J, Warnes G, Alvarez-Lafuente R, Dua P, Meier UC.

J Neuroimmunol. 2017 May 15;306:40-45. doi: 10.1016/j.jneuroim.2017.02.017. Epub 2017 Mar 2.

PMID:
28385186
45.

Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.

Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, DeLuca G, Chandratre S, Leite MI, Vincent A, Palace J.

Brain. 2017 Mar 1;140(3):617-627. doi: 10.1093/brain/aww350.

PMID:
28364548
46.

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.

Juryńczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, Waters P, Kuker W, Craner M, Weir A, DeLuca GC, Kremer S, Leite MI, Vincent A, Jacob A, de Sèze J, Palace J.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):132-136. doi: 10.1136/jnnp-2016-314005. Epub 2016 Oct 8.

PMID:
27951522
47.

Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis.

Tackley G, Vecchio D, Hamid S, Jurynczyk M, Kong Y, Gore R, Mutch K, Woodhall M, Waters P, Vincent A, Leite MI, Tracey I, Jacob A, Palace J.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):165-169. doi: 10.1136/jnnp-2016-314991. Epub 2016 Nov 24.

PMID:
27884934
48.

Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis.

Geraldes R, Esiri MM, DeLuca GC, Palace J.

Brain Pathol. 2017 Nov;27(6):707-722. doi: 10.1111/bpa.12460. Epub 2017 Mar 12. Review.

PMID:
27864848
49.

Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status.

Kong Y, Okoruwa H, Revis J, Tackley G, Leite MI, Lee M, Tracey I, Palace J.

J Neurol Sci. 2016 Sep 15;368:84-8. doi: 10.1016/j.jns.2016.06.041. Epub 2016 Jun 23.

PMID:
27538606
50.

Atypical inflammatory demyelinating syndromes of the CNS.

Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG.

Lancet Neurol. 2016 Aug;15(9):967-981. doi: 10.1016/S1474-4422(16)30043-6. Review.

PMID:
27478954

Supplemental Content

Loading ...
Support Center